Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial

Journal of Psychopharmacology

Volumn 31, Issue 9, 2017, Pages 1166-1175

  Husain, Muhammad I ^a   Chaudhry, Imran B ^b   Husain, Nusrat ^c   Khoso, Ameer B ^b   Rahman, Raza R ^d   Hamirani, Munir M ^e   Hodsoll, John ^f   Qurashi, Inti ^g   Deakin, John F W ^c   Young, Allan H ^f  

^a ST PANCRAS HOSPITAL   (United Kingdom)

^b Pakistan Institute of Leaning and Living   (Pakistan)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^e ABBASI SHAHEED HOSPITAL   (Pakistan)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g MERSEY CARE NHS TRUST   (United Kingdom)

Author keywords

depression; Inflammation; minocycline

Indexed keywords

ANTIDEPRESSANT AGENT; MINOCYCLINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DSM-5; DYSPEPSIA; FEMALE; FLATULENCE; GENERALIZED ANXIETY DISORDER; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HEART ARRHYTHMIA; HUMAN; MALE; MYALGIA; OUTCOME ASSESSMENT; PATIENT HEALTH QUESTIONNAIRE 9; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TREATMENT RESISTANT DEPRESSION; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; MAJOR DEPRESSION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85029701105     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881117724352     Document Type: Article

References (45)

1. Arakawa S, Shirayama Y, Fujita Y, et al (2012) Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behav 100: 601-606.
2. Brooks R, EuroQol Group (1996) EuroQol: The current state of play. Health Policy 37: 53-72.
3. Busner J, Targum SD, (2007) The Clinical Global Impressions Scale. Psychiatry 4: 28-37.
4. Cameron MJ, Kelvin DJ, (2000) Cytokines, Chemokines and Their Receptors: Madame Curie Bioscience Database. Austin, TX: Landes Bioscience.
5. Capuron L, Miller AH, (2011) Immune system to brain signaling: Neuropsychopharmacological implications. Pharmacol Ther 130: 226-238.
6. Carvalho LA, Torre JP, Papadopoulos AS, et al (2013) Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord 148: 136-140.
7. Chaudhry IB, Hallak J, Husain N, et al (2012) Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 26: 1185-1193.
8. Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A, et al (2016) Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: A double-blind, placebo-controlled, randomized trial. Int Clin Psychopharmacol 31: 20-26.
9. Faridhosseini F, Sadeghi R, Farid L, et al (2014) Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 29: 216-223.
10. Faries D, Herrera J, Rayamajhi J, et al (2000) The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 34: 3-10.
11. Fournier JC, DeRubeis RJ, Hollon SD, et al (2010) Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA 303: 47-53.
12. Frank MG, Weber MD, Watkins LR, et al (2015) Stress-induced neuroinflammatory priming: A liability factor in the etiology of psychiatric disorders. Neurobiol Stress 4: 62-70.
13. Gimeno D, Kivimaki M, Brunner EJ, et al (2009) Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 39: 413-423.
14. Grosse L, Carvalho LA, Birkenhager TK, et al (2016) Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. Psychopharmacology (Berl) 233: 1679-1688.
15. Hamilton M, (1960) A rating scale for depression. J Neurol Neurosurg Psychiat 23: 56-62.
16. Hashimoto K, Ishima T, (2010) A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: Translation initiation [corrected] factor eIF4AI. PLoS One 5: e15430.
17. Husain N, Chaudhry N, Fatima B, et al (2014) Antidepressant and group psychosocial treatment for depression: A rater blind exploratory RCT from a low income country. Behav Cogn Psychother 42: 693-705.
18. Kappelmann N, Lewis G, Dantzer R, et al (2016) Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. Epub ahead of print 18 2016. DOI: 10.1038/mp.2016.167.
19. Khandaker GM, Pearson RM, Zammit S, et al (2014) Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: A population-based longitudinal study. JAMA Psychiatry 71: 1121-1128.
20. Kroenke K, Spitzer RL, Williams JB, (2001) The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 16: 606-613.
21. Linde K, Kriston L, Rücker G, et al (2015) Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: Systematic review and network meta-analysis. Ann Fam Med 13: 69-79.
22. Liu YN, Peng YL, Liu L, et al (2015) TNFα mediates stress-induced depression by upregulating indoleamine 2,3-dioxygenase in a mouse model of unpredictable chronic mild stress. Eur Cytokine Netw 26: 15-25.
23. Majidi J, Kosari-Nasab M, Salari AA, (2016) Developmental minocycline treatment reverses the effects of neonatal immune activation on anxiety- and depression-like behaviors, hippocampal inflammation, and HPA axis activity in adult mice. Brain Res Bull 120: 1-13.
24. Mardini HE, Kip KE, Wilson JW, (2004) Crohn's disease: A two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 49: 492-497.
25. Miyaoka T, Wake R, Furuya M, et al (2012) Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry 37: 222-226.
26. Muller N, Schwarz MJ, Dehning S, et al (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11: 680-684.
27. Nelis HJ, De Leenheer AP, (1982) Metabolism of minocycline in humans. Drug Metab Dispos 10: 142-146.
28. Nisar N, Billoo N, Gadit AA, (2004) Prevalence of depression and the associated risks factors among adult women in a fishing community. J Pak Med Assoc 54: 519-525.
29. O'Connor JC, Lawson MA, André C, et al (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14: 511-522.
30. O'Donovan A, Rush G, Hoatam G, et al (2013) Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety 30: 307-314.
31. Oya K, Kishi T, Iwata N, (2014) Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 29: 483-491.
32. Raison CL, Rutherford RE, Woolwine BJ, et al (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 70: 31-41.
33. Regen F, Le Bret N, Hildebrand M, et al (2016) Inhibition of brain retinoic acid catabolism: A mechanism for minocycline's pleiotropic actions? World J Biol Psychiatry 17: 634-640.
34. Rush AJ, Trivedi MH, Wisniewski SR, et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR∗D report. Am J Psychiatry 163: 1905-1917.
35. Rutherford BR, Roose SP, (2013) A model of placebo response in antidepressant clinical trials. Am J Psychiatry 170: 723-733.
36. Sheehan DV, Lecrubier Y, Sheehan KH, et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl. 20): 22-33.
37. Soczynska JK, Mansur RB, Brietzke E, et al (2012) Novel therapeutic targets in depression: Minocycline as a candidate treatment. Behav Brain Res 235: 302-317.
38. Spitzer RL, Kroenke K, Williams JB, et al (2006) A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 166: 1092-1097.
39. Strawbridge R, Arnone D, Danese A, et al (2015) Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol 25: 1532-1543.
40. Targum SD, Wedel PC, Robinson J, et al (2013) A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder. J Psychiatr Res 47: 944-954.
41. US Food and Drug Administration (2016) Drug Study Design: Information Sheet. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm126501.htm
42. Van Gool AR, Kruit WH, Engels FK, et al (2003) Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 25: 11-20.
43. Warner-Schmidt JL, Vanover KE, Chen EY, et al (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by anti-inflammatory drugs in mice and humans. Proc Natl Acad Sci USA 108: 9262-9267.
44. World Health Organization (2017) Depression and Other Common Mental Disorders Global Health Estimates. Geneva: WHO Press.
45. Zalli A, Jovanova O, Hoogendijk WJ, et al (2016) Low-grade inflammation predicts persistence of depressive symptoms. Psychopharmacology (Berl) 233: 1669-1678.